Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
2 Months : From Feb 2020 to Apr 2020
By Jaime Llinares Taboada
Beximco Pharmaceuticals Ltd. said Monday that it has signed a contract for distribution of certain products of Mylan NV in Bangladesh.
The London-listed company said it will receive the exclusive rights to launch Mylan's portfolio of monoclonal antibodies to treat different types of cancers, rheumatoid arthritis, Crohn's disease, ulcerative colitis and other medical conditions.
The first product to be launched, in the first quarter of 2020, will be Ogivri, a breast-cancer drug which is biosimilar to blockbuster drug Herceptin from Roche Holding AG, Beximco said.
Shares at 0900 GMT were up 1.8 pence, or 4.2%, at 45.0 pence.
Write to Jaime Llinares Taboada at email@example.com; @JaimeLlinaresT
(END) Dow Jones Newswires
February 24, 2020 04:23 ET (09:23 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.